Introduction
The Council on Clinical Cardiology of the International Society and Federation of Cardiology has formed several task forces with the World Health Organization in recent years to provide guidelines and recommendations where confusion exists but there is sufficient experience for conclusions to be generalized by international experts. In November 1984, the council recommended that a task force be formed for coronary angioplasty. This task force has described current indications and interpretation of results, and made recommendations regarding training, equipment, and preangioplasty and postangioplasty management. The council has also generated guidelines for coronary angioplasty that appear to be internationally acceptable. The The use of coronary angioplasty in symptomatic patients with multivessel disease has grown rapidly. In asymptomatic patients, all benefit to the patient must accrue from a presumed reduction in complications of coronary disease. Individuals with objective evidence of ischemia but no angina may have faulty warning systems or silent ischemia and an adverse prognosis.
Asymptomatic patients are identified through exercise stress testing or following myocardial infarction. Those with high grade lesions of single vessels supplying large areas of left ventricular myocardium are frequently treated with angioplasty.
Patients with significant obstruction in two or more vessels and significant myocardial ischemia can be considered for angioplasty if the probability of success is high, and if angioplasty can be strategically performed so that large amounts of myocardium are not placed in sudden jeopardy.
Documented Variant Angina
In patients with variant angina and spasm in the affected stenotic artery, angioplasty can improve the patient's condition if the fixed obstruction is significant. If the obstruction is less severe, symptoms frequently persist after angioplasty and are often accompanied by restenosis. Therefore, angioplasty is not recommended for patients with mild stenoses.
Acute Myocardial Infarction
Patients with acute myocardial infarction whose symptoms have been present for less than three to four hours are sometimes treated with immediate coronary angioplasty. The use of angioplasty as the first mode of therapy is controversial, but there is evidence that immediate angioplasty provides reperfusion, improved left ventricular function, and survival.
Angina After Coronary Bypass Surgery
Angina recurs in approximately 50% of patients during the first seven to eight years after coronary bypass surgery. Several mechanisms may be responsible for these new symptoms. New significant lesions are frequently observed in native vessels that may be suitable for coronary angioplasty. In some instances, the bypass graft is totally occluded but the proximal coronary lesion is still technically suitable for coronary angioplasty. In other cases, the graft is patent, and stenoses in the distal coronary artery can be dilated through the graft. Finally, narrowings of the graft itself that are discrete and single can be dilated. The distal artery anastomosis is the ideal location for coronary angioplasty in both the saphenous vein and internal mammary artery grafts. Dilatation of the graft to the aortic anastomotic site and obstructions in the body of the graft are followed by a high rate of restenosis. Definition of Anatomic Restenosis Previously proposed criteria for recurrent stenosis relied almost exclusively on angiographic reevaluation in contrast to primary success criteria.8-2' Until recently, the two most frequently used restenosis criteria were an increase of at least 30% in diameter stenosis from immediate post-PTCA to follow-up angiogram, or a loss of at least 50% of total gain in percent diameter stenosis achieved at PTCA.
More recently, several investigators have used a third definition of restenosis, an immediate post-PTCA diameter stenosis of less than 50% that increases to 50% or greater at follow-up.
Whenever a specific threshold is used to identify restenosis, the task force recommends this definition. In general, angiographic change is detectable when there is at least 20% visual increase in percent stenosis from early post-PTCA to follow-up angiogram (or at least 10% by quantitative assessment). In the future, it would be preferable to present quantitative measurements (caliper or computerassisted) of the extent to which the lesion residual lumen diameter changed from post-PTCA measurement back to pre-PTCA measurement.22 Moreover, the status of blood pressure and vasodilator medication at the time of angiography is also relevant to the evaluation of changes in coronary lesion dimension over time.
Finally, in a given patient, clinical significance of a lesion that meets these angiographic criteria for restenosis must be judged on severity of symptoms, exercise tolerance, and extent of jeopardized myocardium, among other factors. Multilesion Versus Multivessel PTCA There is still some confusion about what should distinguish multivessel angioplasty from multilesion angioplasty in a single coronary artery. To standardize these definitions, the task force suggests that the widely accepted coronary anatomy nomenclature described by the Coronary Artery Surgery Study (CASS) group be followed.23 Multilesion PTCA refers to attempted dilatation of lesions in more than one segment of a major coronary artery, using the CASS nomenclature. Examples of multilesion PTCA in a single major coronary artery include 1) attempted dilatation of lesions in segments 13 (mid left anterior descending artery) and 15 (first diagonal artery), and 2) attempted dilatation of lesions in segments 19 (distal circumflex artery) and 20 
Angioplasty Procedural Equipment
Equipment from a variety of manufacturers is suitable for performance of PTCA. All laboratories performing the procedure should have a selection of equipment that includes a complete range of guiding catheters, balloon catheters from 2-4 mm in diameter, and a range of steerable guide wire systems.
Several variations on the technique of coronary angioplasty are available and the experienced operator should be familiar with as many as possible. It is prudent for the operator and the laboratory staff to be completely familiar with the method that works best for them. At the present time, some form of steerable guide wire or a soft-tipped fixed balloon catheter system is used by all operators. All of these systems are steerable.
Angioplasty results should be assessed by each operator with the technique that serves his or her needs best. Both angiographic and hemodynamic measures of angioplasty success are helpful in guiding performance of the procedure. Some systems do not allow for pressure measurement and in those cases, techniques for excellent angiographic assessment must be available on-line. If pressures are measured, then equisensitive pressure-monitoring systems must be in place, be maintained properly, and used correctly.
Adequate performance of angioplasty is largely a result of extensive operator experience and is inseparable from training requirements for professional personnel. Radiation Sources Protection of personnel from exposure to radiation is critically important. Currently, methods of reducing x-ray radiation are available on standard equipment such as an optimal TV chain and image intensifier, an x-ray beam with automatic collimation, a correct field size on the image intensifier, a carbon fiber scattered radiation grid, a carbon fiber table top, and a correct tube filter. These measures may result in a dosage reduction of up to 50%, a lower x-ray tube loading with a smaller focal spot, and improved picture quality. Whenever possible, lower level radiation video imaging should be substituted for higher radiation cine filming.
Further radiation reduction may be achieved by using extra equipment such as a video image processor. Fluoroscopy filtering, pulsed fluoroscopy, and image hold techniques will considerably reduce the duration of fluoroscopy examination. During cinematography, gap filling and selection of a reference image will improve the operator's visual perception and make frequent cinefilming unnecessary. Pathfinding using a reference monitor, automated video replay after cinematography using a video disc or digital techniques, and automatic and instant storage of the image with a video recorder will all result in a further reduction in x-ray exposure. All personnel should be protected against radiation by special aprons, eyeglasses, thyroid protection, and extra shielding of the x-ray tube.
Surgical Back-Up and Coverage Specific emergency situations may occur during coronary angioplasty in which coronary surgery is the most expeditious, if not the only, method to maintain myocardial perfusion of severely ischemic myocardium.4-7 These situations include failed angioplasty with development of active ischemia, obstructive arterial dissection, thrombosis, or less commonly, cardiac vessel perforation, cardiac tamponade, and peripheral artery complications. Although multi-ISFClWHO Task Force Coronary Angioplasty 787 ple techniques have been developed, including repeat angioplasty and catheters for distal perfusion, these measures may only be temporizing.
The incidence ofcomplications necessitating emergency surgery is increased for lesions located in tortuous vessels, at bifurcation points or sharp bends, and for lesions that are long (> 1 cm), deeply ulcerated, or have associated intraluminal thrombus. The increased risk that accompanies acute closure of a major artery, jeopardizing large amounts of myocardium, should be recognized and particularly close surgical back-up arrangements should be made in these instances. Although there is a tendency to categorize angioplasty procedures as having low, moderate, or high risk, situations do occur in low-risk procedures that lead to catastrophic complications. For instance, angioplasty of totally occluded vessels may be less likely to provoke a greater degree of myocardial ischemia or damage than that already present, but acute reclosure, left main coronary artery dissection, and vessel perforation can occur. It should be assumed that any coronary interventional procedure has the potential for a catastrophic complication that can jeopardize the patient's life. Consultation with a cardiovascular surgeon or arrangements for appropriate surgical coverage prior to performance of any angioplasty procedure is mandatory. The cardiologist and surgeon performing the angioplasty should agree on the relative risk to a particular patient for a complication that would necessitate emergency surgery. Depending on this determination, a level of standby should be decided, along with a potential management plan in the event of failed PTCA without complications. The Preangioplasty and Postangioplasty Management Before a patient is considered a candidate for coronary angioplasty, risk factors should be corrected to the greatest possible extent. The patient and family should be fully informed of the goals and risks of coronary angioplasty, including the possible need for emergency cardiac surgery. [4] [5] [6] [7] Medication is given with the aim of reducing the potential for arterial reclosure and restenosis. Coronary angioplasty can stimulate coronary spasm or increase a preexisting tendency toward spasm. The underlying mechanism probably relates to the traumatization of the endothelium and platelet deposition with release of vasoactive substances. Therefore, medications that decrease sympathetic coronary tone and reduce platelet deposition are recommended during and after the procedure. Long-acting nitrates or calcium antagonists plus antiplatelet agents are usually prescribed. Since p-blocking drugs increase the a-adrenergic tone of coronary arteries, they may increase the potential for coronary artery spasm. Whenever possible, these drugs should be reduced or withdrawn prior to angioplasty, or long-acting nitrates or calcium channel blockers should also be prescribed. Similarly, for the first several weeks after a successful procedure, p-blocker drugs should be prescribed only in conjunction with long-acting nitrates or calcium channel blocking drugs.
Coronary thrombosis is one of the major causes of complications during angioplasty. In addition, platelet aggregation probably plays a major role in the genesis of restenosis after successful angioplasty. In general, anticoagulation with warfarin has not been more effective than drugs that inhibit platelet aggregation and deposition. Following successful angioplasty, acetylsalicylic acid is usually given in doses ranging from 100-1,500 mg a day in current practice. Variable doses of dypyridamole (75-400 mg a day) are also prescribed. Neither a clear-cut benefit nor optimum dose for these agents has been defined, but randomized placebocontrolled trials of the effectiveness of these agents in angioplasty are nearing completion.
Similarly the use of heparin during and immediately after the procedure is presumed to be beneficial, but no randomized study demonstrating its benefits exists. Because of the use of multiple catheters for extended periods during coronary angioplasty, there is general agreement about the use of heparin anticoagulation during the procedure. Due to increased rates of abrupt reocclusion in patients in whom protamine was employed to reverse heparin anticoagulation, its routine use is not recommended at the completion of a procedure.
There is much greater variability in the prescription of heparin following successful angioplasty. Current treatment protocols range from no additional heparin at completion to infusions of heparin for 24- There is currently an explosion in new devices and approaches designed to overcome the current limitations of angioplasty practice.28-34 Balloon Technology Advances in balloon catheter design include highpressure balloons for displacing noncompliant lesions and extremely low-profile balloons that allow crossing very tight lesions, particularly those located distally in vessels where mechanical support from the guide catheter system is difficult. Guide wires are being evaluated that have balloon catheters and are so small that theoretically any severely stenosed arterial segment with a residual lumen can be crossed and dilated.
Other balloon devices will allow special applications. Balloon systems are being designed for introduction over guide wires in such a way that the balloon can be removed for angiographic assessment while the wire remains in place in the artery.
A "monorail" system using short guide wires and standard angioplasty balloons with long guide wire systems are currently being evaluated. Some currently available catheters allow distal perfusion of arterialized blood or oxygenated blood substitutes. Balloons are also being developed that allow blood to enter the lumen of the balloon proximal to the lesion and exit distally while the balloon is still inflated, enabling longer inflations
Laser Technology
It is hypothesized that by removing atherosclerotic obstructions through vaporization of plaque, laser angioplasty may be more effective than balloon angioplasty. However, to date, the technique has been limited by inadequate delivery systems resulting in an unacceptably high perforation rate and the creation of small recanalized channels that have a poor long-term patency. Attempts to solve the problems of vessel perforation and thrombosis after laser angioplasty have been directed along several lines of investigation. One approach has been to preferentially increase absorption by atherosclerotic tissue of laser radiation by using various compounds such as hematoporphyrin or tetracycline. Whether this will be clinically effective in removing atherosclerotic obstructions remains to be determined. Atherosclerotic lesions can also be distinguished from normal tissue by laser-conducted spectrographic analysis. This technique may represent an alternative means of guiding the selective ablation of atheroma without damaging normal arterial wall. This concept also requires confirmation of safety and efficacy. Other approaches to diminishing vessel perforation with laser energy include the use of lasers with a shorter pulse duration, such as the excimer laser, direct visualization using an angioscope, and the use of specially designed balloon catheters and heated metal tips to allow more circumferential diffusion of the laser energy. Other forms of energy that can be delivered through a catheter system to remove or displace atherosclerotic material in the coronary arteries are also being developed. Other Mechanical Developments
Other mechanical means of removing atherosclerotic plaque are under active investigation, including a biotome device that ' . shaves away" the obstructing lesion, resulting in an atherectomy.
Intracoronary stents or devices that are placed in a dilated segment of a coronary artery to mechanically maintain lumen size have been developed and are now available for clinical trials. It is likely that the capabilities of modern technology will introduce as yet unknown devices that will restore coronary blood flow by eliminating obstructing lesions without major surgical intervention. Each of these techniques will require thoughtful evaluation by controlled trials and will ultimately be evaluated against the current gold standards for revascularization, that is, coronary bypass surgery or PTCA.
